Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Somatuline

 
National Institutes of Health

Related topics

Related topics

7 relations
0.3 ML lanreotide 300 MG/ML Prefilled Syringe [Somatuline]0.5 ML lanreotide 240 MG/ML Prefilled Syringe [Somatuline]flutamide/leuprolide/somatuline/suraminsomatuline/suramin

Broader (3)

OctreotideSandostatinlanreotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).
CONTEXT Congenital hyperinsulinism (CH) may be treated conservatively in many children with octreotide given by multiple sc… Expand
Review
2001
Review
2001
Somatostatin, Its Receptors and Analogs, in Lung Cancer
Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
1995
1995
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone‐refractory prostate cancer
Background. Somatuline, a somatostatin analogue, as proven to be effective in several animal models of prostate cancer… Expand
1995
1995
Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
Somatostatin analogues have been shown to suppress some hormones and growth factors involved in breast tumour growth and a direct… Expand
1994
1994
Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly.
The aim of this work was to assess the use of a sustained-release formulation of somatuline, a long-acting analogue of… Expand
  • figure 1
  • figure 2
  • table I
Highly Cited
1994
Highly Cited
1994
[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
This study was performed to evaluate whether the presence or absence of somatostatin receptors in malignant carcinoid tumours… Expand
  • table 1
Highly Cited
1993
Highly Cited
1993
Somatostatin analogue phase I trials in neuroendocrine neoplasms.
To further investigate the antineoplastic efficacy and safety of somatostatin analogues, 2 trials were performed. Octreotide, SMS… Expand
Highly Cited
1993
Highly Cited
1993
Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
Positron emission tomography (PET) makes it possible to study effects of medical treatment in vivo. Carcinoid tumors with liver… Expand
Highly Cited
1990
Highly Cited
1990
Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline).
Four human small cell lung carcinomas, NCI-H69, NCI-N417, NCI-H345, LX-1, and a non-small cell lung carcinoma, H-165, implanted s… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
1990
1990
Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration.
This study addresses, in an animal tumor model, the clinical problem of "escape from castration inhibition." Somatuline (BIM… Expand
  • figure I
  • table 1
  • table 2
  • figure 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE